Tesla shares (TSLA) tumble as disappointing quarterly results raise questions over Elon Musk’s AI and robotics pivot
Tesla shares tumbled the most in more than a year after disappointing quarterly results raised questions about Elon Musk’s plan […]
NCA study — TradingView News
Research from the National Cryptocurrency Association (NCA), an organization backed by Ripple Labs, broke down the economic impact of the
Investing Strategy
GracoRoberts Announces Strategic Investment from Tinicum
Partnership Will Accelerate GracoRoberts’ Growth as a Trusted Supplier of Mission-Critical Materials to the Global Aerospace and Defense Industry ARLINGTON,
Stock Market News and Research Tools
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain,
Report highlights crypto’s growing economic footprint in the US
Research highlights the growing role of the US crypto industry in supporting jobs, high-value careers and broader economic growth beyond
Rob Wilson featured in Yahoo Finance discussing how young Australians are building wealth with ETFs
Selfwealth by Syfe Director of Investment Strategy, Rob Wilson, was recently featured in Yahoo Finance Australia, providing commentary on how
Tesla Shares Slump to Near One-Year Low, Technical Warning Signals Potential for Over 30% Further Drop
TradingKey – Tesla shares plummeted over 14% post-earnings, breaking below key support at $340, with significant downward pressure ahead. On
Europe’s Biggest Crypto Decision Isn’t About Stablecoins but About Prediction Markets
While the industry spent the summer arguing about stablecoin reserves and DeFi certification schemes, the most consequential question in European
Strategy Has Now Gone 4 Weeks Without Buying Bitcoin. Should Investors Be Concerned?
Strategy (MSTR -6.38%) was a huge winner from 2024 through 2025 as it aggressively issued stock and debt to fund
Analysis-AstraZeneca ‘magic’ faces rare test after trial failure, share slide
By Maggie Fick LONDON, July 24 (Reuters) – AstraZeneca’s long-time CEO Pascal Soriot has rarely put a foot wrong. The